Antiresorptive Therapy for Osteoporosis in Older Subjects

2.

Tran

T

,

Bliuc

D

,

Hansen

L

,

Abrahamsen

B

,

van den Bergh

J

,

Eisman

JA

, et al.

Persistence of excess mortality following individual nonhip fractures: a relative survival analysis

.

J Clin Endocrinol Metab

.

2018

;

103

(

9

):

3205

–

14

.

3.

Abrahamsen

B

,

Nissen

N

,

Hermann

AP

,

Hansen

B

,

Bärenholdt

O

,

Vestergaard

P

, et al.

When should densitometry be repeated in healthy peri- and postmenopausal women: the Danish osteoporosis prevention study

.

J Bone Miner Res

.

2002

;

17

(

11

):

2061

–

7

.

4.

Kanis

JA

,

Johnell

O

,

Oden

A

,

Dawson

A

,

De Laet

C

,

Jonsson

B

.

Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds

.

Osteoporos Int

.

2001

;

12

(

12

):

989

–

95

.

5.

Ziegenhain

F

,

Mittlmeier

AS

,

Pape

HC

,

Neuhaus

V

,

Canal

C

.

Influence of age on outcome following rib fractures: a case-control analysis

.

Geriatr Orthop Surg Rehabil

.

2024

;

15

:

21514593241280879

.

6.

Wu

C-Y

,

Tsai

C-F

,

Hsu

Y-H

,

Yang

H-Y

.

Exploring mortality risk factors and specific causes of death within 30 days after hip fracture hospitalization

.

Sci Rep

.

2024

;

14

(

1

):

27544

.

7.

Azevedo

SF

,

Mazeda

C

,

Silva

SP

,

Barcelos

A

.

Two-year mortality predictors in fragility fractures: a medical records review study

.

J Clin Rheumatol

.

2024

;

30

(

6

):

239

–

42

.

8.

Miller

PD

.

Underdiagnosis and undertreatment of osteoporosis: the battle to be won

.

J Clin Endocrinol Metab

.

2016

;

101

(

3

):

852

–

9

.

9.

Vestergaard

P

,

Rejnmark

L

,

Mosekilde

L

.

Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark

.

Osteoporos Int

.

2005

;

16

(

2

):

134

–

41

.

10.

McCloskey

E

,

Rathi

J

,

Heijmans

S

,

Blagden

M

,

Cortet

B

,

Czerwinski

E

, et al.

The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study

.

Osteoporos Int

.

2021

;

32

(

2

):

251

–

9

.

11.

Chapuy

MC

,

Arlot

ME

,

Duboeuf

F

,

Brun

J

,

Crouzet

B

,

Arnaud

S

, et al.

Vitamin D3 and calcium to prevent hip fractures in elderly women

.

N Engl J Med

.

1992

;

327

(

23

):

1637

–

42

.

12.

Eastell

R

,

Rosen

CJ

,

Black

DM

,

Cheung

AM

,

Murad

MH

,

Shoback

D

.

Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline

.

J Clin Endocrinol Metab

.

2019

;

104

(

5

):

1595

–

622

.

13.

Shah

VP

,

Nayfeh

T

,

Alsawaf

Y

,

Saadi

S

,

Farah

M

,

Zhu

Y

, et al.

A systematic review supporting the Endocrine Society clinical practice guidelines on vitamin D

.

J Clin Endocrinol Metab

.

2024

;

109

(

8

):

1961

–

74

.

14.

Cameron

ID

,

Dyer

SM

,

Panagoda

CE

,

Murray

GR

,

Hill

KD

,

Cumming

RG

, et al.

Interventions for preventing falls in older people in care facilities and hospitals

.

Cochrane Database Syst Rev

.

2018

;

9

(

9

):

CD005465

.

15.

Tang

BMP

,

Eslick

GD

,

Nowson

C

,

Smith

C

,

Bensoussan

A

.

Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis

.

Lancet

.

2007

;

370

(

9588

):

657

–

66

.

16.

Oda

T

,

Jödicke

AM

,

Robinson

DE

,

Delmestri

A

,

Keogh

RH

,

Prieto-Alhambra

D

.

Oral bisphosphonates are associated with increased risk of severe acute kidney injury in elderly patients with complex health needs: a self-controlled case series in the United Kingdom

.

J Bone Miner Res

.

2022

;

37

(

7

):

1270

–

8

.

17.

Bauer

DC

,

Black

DM

,

Dell

R

,

Fan

B

,

Smith

CD

,

Ernst

MT

, et al.

Bisphosphonate use and risk of atypical femoral fractures: a Danish case-cohort study with blinded radiographic review

.

J Clin Endocrinol Metab

.

2024

;

109

(

11

):

e2141

–

50

.

18.

Black

DM

,

Geiger

EJ

,

Eastell

R

,

Vittinghoff

E

,

Li

BH

,

Ryan

DS

, et al.

Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates

.

N Engl J Med

.

2020

;

383

(

8

):

743

–

53

.

19.

Black

DM

,

Reiss

TF

,

Nevitt

MC

,

Cauley

J

,

Karpf

D

,

Cummings

SR

.

Design of the fracture intervention trial

.

Osteoporos Int

.

1993

;

3

(

Suppl 3

):

S29

–

39

.

20.

Bone

HG

,

Downs

RW

,

Tucci

JR

,

Harris

ST

,

Weinstein

RS

,

Licata

AA

, et al.

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers

.

J Clin Endocrinol Metab

.

1997

;

82

(

1

):

265

–

74

.

21.

Ensrud

KE

,

Black

DM

,

Palermo

L

,

Bauer

DC

,

Barrett-Connor

E

,

Quandt

SA

, et al.

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial

.

Arch Intern Med

.

1997

;

157

(

22

):

2617

–

24

.

22.

Hochberg

MC

,

Thompson

DE

,

Black

DM

,

Quandt

SA

,

Cauley

J

,

Geusens

P

, et al.

Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures

.

J Bone Miner Res

.

2005

;

20

(

6

):

971

–

6

.

23.

Axelsson

KF

,

Wallander

M

,

Johansson

H

,

Lundh

D

,

Lorentzon

M

.

Hip fracture risk and safety with alendronate treatment in the oldest-old

.

J Intern Med

.

2017

;

282

(

6

):

546

–

59

.

24.

Välimäki

MJ

,

Farrerons-Minguella

J

,

Halse

J

,

Kröger

H

,

Maroni

M

,

Mulder

H

, et al.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial

.

Clin Ther

.

2007

;

29

(

9

):

1937

–

49

.

25.

Boonen

S

,

McClung

MR

,

Eastell

R

,

El-Hajj Fuleihan

G

,

Barton

IP

,

Delmas

P

.

Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old

.

J Am Geriatr Soc

.

2004

;

52

(

11

):

1832

–

9

.

26.

McClung

MR

,

Geusens

P

,

Miller

PD

,

Zippel

H

,

Bensen

WG

,

Roux

C

, et al.

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group

.

N Engl J Med

.

2001

;

344

(

5

):

333

–

40

.

27.

Reginster

J

,

Minne

HW

,

Sorensen

OH

,

Hooper

M

,

Roux

C

,

Brandi

ML

, et al.

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group

.

Osteoporos Int

.

2000

;

11

(

1

):

83

–

91

.

28.

Delmas

PD

,

Recker

RR

,

Chesnut

CH

,

Skag

A

,

Stakkestad

JA

,

Emkey

R

, et al.

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

.

Osteoporos Int

.

2004

;

15

(

10

):

792

–

8

.

29.

Chesnut

CH

,

Skag

A

,

Christiansen

C

,

Recker

R

,

Stakkestad

JA

,

Hoiseth

A

, et al.

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis

.

J Bone Miner Res

.

2004

;

19

(

8

):

1241

–

9

.

30.

Ettinger

MP

,

Felsenberg

D

,

Harris

ST

,

Wasnich

R

,

Skag

A

,

Hiltbrunner

V

, et al.

Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age

.

J Rheumatol

.

2005

;

32

(

10

):

1968

–

74

.

31.

Black

DM

,

Delmas

PD

,

Eastell

R

,

Reid

IR

,

Boonen

S

,

Cauley

JA

, et al.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

.

N Engl J Med

.

2007

;

356

(

18

):

1809

–

22

.

32.

Lyles

KW

,

Colón-Emeric

CS

,

Magaziner

JS

,

Adachi

JD

,

Pieper

CF

,

Mautalen

C

, et al.

Zoledronic acid and clinical fractures and mortality after hip fracture

.

N Engl J Med

.

2007

;

357

(

18

):

1799

–

809

.

33.

Reid

IR

,

Black

DM

,

Eastell

R

,

Bucci-Rechtweg

C

,

Su

G

,

Hue

TF

, et al.

Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams

.

J Clin Endocrinol Metab

.

2013

;

98

(

2

):

557

–

63

.

34.

Boonen

S

,

Black

DM

,

Colón-Emeric

CS

,

Eastell

R

,

Magaziner

JS

,

Eriksen

EF

, et al.

Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older

.

J Am Geriatr Soc

.

2010

;

58

(

2

):

292

–

9

.

35.

Cummings

SR

,

San Martin

J

,

McClung

MR

,

Siris

ES

,

Eastell

R

,

Reid

IR

, et al.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

.

N Engl J Med

.

2009

;

361

(

8

):

756

–

65

.

36.

Boonen

S

,

Adachi

JD

,

Man

Z

,

Cummings

SR

,

Lippuner

K

,

Törring

O

, et al.

Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk

.

J Clin Endocrinol Metab

.

2011

;

96

(

6

):

1727

–

36

.

37.

McClung

MR

,

Boonen

S

,

Törring

O

,

Roux

C

,

Rizzoli

R

,

Bone

HG

, et al.

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

.

J Bone Miner Res

.

2012

;

27

(

1

):

211

–

8

.

38.

Jeong

C

,

Ha

J

.

The effect of denosumab on bone mass in super elderly patients

.

J Bone Metab

.

2020

;

27

(

2

):

119

–

24

.

39.

Yoon

S-H

,

Kim

K

,

Kim

K-C

.

The effect of denosumab in elderly patients regarding bone density and fracture risk

.

J Bone Metab

.

2023

;

30

(

3

):

275

–

82

.

40.

Jackson

RD

,

LaCroix

AZ

,

Gass

M

,

Wallace

RB

,

Robbins

J

,

Lewis

CE

, et al.

Calcium plus vitamin D supplementation and the risk of fractures

.

N Engl J Med

.

2006

;

354

(

7

):

669

–

83

.

41.

Radford

LT

,

Bolland

MJ

,

Mason

B

,

Horne

A

,

Gamble

GD

,

Grey

A

, et al.

The Auckland calcium study: 5-year post-trial follow-up

.

Osteoporos Int

.

2014

;

25

(

1

):

297

–

304

.

42.

Thiele

I

,

Linseisen

J

,

Meisinger

C

,

Schwab

S

,

Huth

C

,

Peters

A

, et al.

Associations between calcium and vitamin D supplement use as well as their serum concentrations and subclinical cardiovascular disease phenotypes

.

Atherosclerosis

.

2015

;

241

(

2

):

743

–

51

.

43.

Bolland

MJ

,

Grey

A

,

Avenell

A

,

Gamble

GD

,

Reid

IR

.

Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis

.

BMJ

.

2011

;

342

:

d2040

.

44.

Cecilia

D

,

Jódar

E

,

Fernández

C

,

Resines

C

,

Hawkins

F

.

Effect of alendronate in elderly patients after low trauma hip fracture repair

.

Osteoporos Int

.

2009

;

20

(

6

):

903

–

10

.

45.

Cummings

SR

,

Black

DM

,

Thompson

DE

,

Applegate

WB

,

Barrett-Connor

E

,

Musliner

TA

, et al.

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

.

JAMA

.

1998

;

280

(

24

):

2077

–

82

.

46.

Reid

IR

,

Horne

AM

,

Mihov

B

,

Stewart

A

,

Garratt

E

,

Wong

S

, et al.

Fracture prevention with zoledronate in older women with osteopenia

.

N Engl J Med

.

2018

;

379

(

25

):

2407

–

16

.

47.

Reid

IR

,

Horne

AM

,

Mihov

B

,

Stewart

A

,

Garratt

E

,

Wiessing

KR

, et al.

Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial

.

J Intern Med

.

2019

;

286

(

2

):

221

–

9

.

48.

Abrahamsen

B

,

Eiken

P

,

Prieto-Alhambra

D

,

Eastell

R

.

Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study

.

BMJ

.

2016

;

353

:

i3365

.

49.

Khan

AA

,

Morrison

A

,

Hanley

DA

,

Felsenberg

D

,

McCauley

LK

,

O’Ryan

F

, et al.

Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus

.

J Bone Miner Res

.

2015

;

30

(

1

):

3

–

23

.

50.

Zullo

AR

,

Lee

Y

,

Lary

C

,

Daiello

LA

,

Kiel

DP

,

Berry

SD

.

Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study

.

Osteoporos Int

.

2021

;

32

(

3

):

565

–

73

.

51.

Greenspan

SL

,

Perera

S

,

Haeri

NS

,

Nace

DA

,

Resnick

NM

.

Denosumab for osteoporosis in older adults in long-term care: a randomized trial

.

J Am Geriatr Soc

.

2025

;

73

(

2

):

445

–

57

.

52.

Chen

J

,

Smerdely

P

.

Hypocalcaemia after denosumab in older people following fracture

.

Osteoporos Int

.

2017

;

28

(

2

):

517

–

22

.

53.

Broadwell

A

,

Chines

A

,

Ebeling

PR

,

Franek

E

,

Huang

S

,

Smith

S

, et al.

Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease

.

J Clin Endocrinol Metab

.

2021

;

106

(

2

):

397

–

409

.

54.

Nayak

S

,

Roberts

MS

,

Greenspan

SL

.

Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment

.

PLoS One

.

2012

;

7

(

3

):

e32879

.

55.

Pham

AN

,

Datta

SK

,

Weber

TJ

,

Walter

LC

,

Colón-Emeric

CS

.

Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy

.

J Am Geriatr Soc

.

2011

;

59

(

9

):

1642

–

9

.

56.

Ito

K

.

Cost-effectiveness of single-dose zoledronic acid for nursing home residents with osteoporosis in the USA

.

BMJ Open

.

2018

;

8

(

9

):

e022585

.

57.

Akehurst

R

,

Brereton

N

,

Ariely

R

,

Lusa

T

,

Groot

M

,

Foss

P

, et al.

The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands

.

J Med Econ

.

2011

;

14

(

1

):

53

–

64

.

58.

Fardellone

P

,

Cortet

B

,

Legrand

E

,

Bresse

X

,

Bisot-Locard

S

,

Vigneron

AM

, et al.

Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis

.

Joint Bone Spine

.

2010

;

77

(

1

):

53

–

7

.

59.

Hiligsmann

M

,

Reginster

J-Y

.

Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women

.

Bone

.

2010

;

47

(

1

):

34

–

40

.

60.

Mori

T

,

Crandall

CJ

,

Ganz

DA

.

Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan

.

Osteoporos Int

.

2017

;

28

(

5

):

1733

–

44

.

61.

Silverman

S

,

Agodoa

I

,

Kruse

M

,

Parthan

A

,

Orwoll

E

.

Denosumab for elderly men with osteoporosis: a cost-effectiveness analysis from the US payer perspective

.

J Osteoporos

.

2015

;

2015

:

627631

.

62.

Händel

MN

,

Cardoso

I

,

von Bülow

C

,

Rohde

JF

,

Ussing

A

,

Nielsen

SM

, et al.

Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials

.

BMJ

.

2023

;

381

:

e068033

.

63.

Clemens

KK

,

Jeyakumar

N

,

Ouédraogo

AM

,

Thain

J

,

Khan

T

.

Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study

.

Arch Osteoporos

.

2020

;

15

(

1

):

133

.